Tabimorelin
Tabimorelin did not show beneficial effects on GH release in adult
patients with GHD in a Phase II study [17]. Also, tabimorelin has
been reported to inhibit CYP3A4, which can lead to unexpected side
effects [18]. To overcome this disadvantage, Novo Nordisk has
developed some compounds derived from tabimorelin, such as NNC-26-1167,
although they have not yet been evaluated in clinical trials.